Migraine deal a headache for Retrophin's Transcept quest?
This article was originally published in Scrip
In a move that shifts the sands under Retrophin's hostile buyout bid for Transcept Pharmaceuticals, Transept has acquired global rights to a preclinical candidate for acute migraine using novel delivery technology developed by Japan's Shin Nippon Biomedical Laboratories (SNBL).
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.